OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
July 03, 2022
Biologics are forming a greater proportion of the development pipeline, but there are still some formulation difficulties to overcome to ensure clinical and commercial success.
Single-cell analytical technologies can deepen the understanding of cell biology and, therefore, disease mechanisms.
Lack of toxicity data and poor physicochemical properties must be overcome.
July 02, 2022
Pharma should expand on successful cell therapies in oncology by applying these development and manufacturing methods to neuronal cell therapies.
As we reach further afield in the molecular universe, we encounter new types of problems to resolve.
Systemic inefficiencies in the pharmaceutical industry undermine problem-solving efforts.
June 30, 2022
Inceptor Bio and the University of Minnesota aim to build a novel iPSC platform to accelerate cell therapy drug development.
June 27, 2022
ImmunoGen has formed a research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates for cancers with high unmet needs.
The Sanofi-GSK vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial with a high-Omicron environment.
June 24, 2022
Novartis will endorse the Kigali Declaration on neglected tropical diseases and invest $250 million for R&D.